Variability of Plasma Homovanillic Acid Over 13 Months in Patients with Schizophrenia; Relationship with the Clinical Response and the Wisconsin Card Sort Test

Zumárraga, Mercedes; González‐Torres, Miguel Ángel; Arrúe, Aurora; Dávila, Ricardo; Dávila, Wendy; Inchausti, Lucía; Pérez-Cabeza, Lucía; Fernández‐Rivas, Aranzazu; Bustamante, Sonia; Basterreche, Nieves; Guimón, José

doi:10.1007/s11064-011-0448-8

Cited by 5 publications

(4 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Symptomatic improvement and reaching remission status was most pronounced in FEP patients, as repeatedly reported by other investigators [10,32]. These observations may be related with the individual's state of neuroplasticity, as reflected by the ability to alter pHVA levels, especially since lack of plasticity is hypothesized to be related with loss of antipsychotic efficacy [33,34], poor prognosis and chronic course of disease [12,35]. …”

Section: Discussionsupporting

confidence: 65%

Relationship between Plasma Homovanillic Acid and Outcome in Patients with Psychosis Spectrum Disorders

Kerkhof

Fekkes²,

Heijden³

et al. 2015

Neuropsychobiology

View full text Add to dashboard Cite

Background: Psychosis spectrum disorders, especially schizophrenia, have been linked to disturbed dopaminergic activity in the brain. Plasma homovanillic acid (pHVA) levels partly represent dopaminergic metabolism in the central nervous system. In the present study associations between (changes in) pHVA levels, symptom severity and symptomatic improvement in patients with psychoses were investigated. Methods: From a total of 80 patients, 58 fulfilled all inclusion criteria and their symptom profile and severity were assessed by means of the Comprehensive Assessment of Symptoms and History (CASH), the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression Scale for Severity and Improvement (CGI-S/CGI-I) at baseline and after 6 weeks of antipsychotic treatment. After inclusion, all patients were prescribed first- or second-generation antipsychotics by their treating psychiatrist. A total of 12 patients had first-episode psychosis (FEP). At both time points, pHVA levels were measured. Subsequently, pHVA levels were compared with an age-matched control sample and changes in pHVA levels (ΔpHVA) after treatment were associated with clinical parameters. Results: Before analyses, data were scrutinized for possible confounders, particularly gender, smoking, medication status (including antipsychotic class), and recent drug use. The pHVA levels in patients were not different from those in controls. Treatment resulted in a significant decrease of all parameters. Symptomatic improvement as well as ΔpHVA was most pronounced in FEP patients. Conclusion: These findings show that patients with FEP have a more favourable outcome than non-FEP patients and that greater ΔpHVA also suggests that FEP patients still have the capacity to adjust dopaminergic neurotransmission.

show abstract

Section: Discussionsupporting

confidence: 65%

Relationship between Plasma Homovanillic Acid and Outcome in Patients with Psychosis Spectrum Disorders

Kerkhof

Fekkes²,

Heijden³

et al. 2015

Neuropsychobiology

View full text Add to dashboard Cite

show abstract

“…In a study of schizophrenia patients treated with AAP, HVA levels were found to be increased after treatment [ 49 ]. In the same study, a positive correlation was found between HVA level and PANSS positive subscale [ 50 ]. Plasma HVA levels were found to associate with psychotic symptoms.…”

Section: Discussionmentioning

confidence: 92%

“…Plasma HVA levels decreased in the first week of treatment and were correlated with good prognosis [ 53 , 54 ]. In several studies, HVA levels were reported to be positively correlated with clinical improvements in schizophrenia [ 50 ]. In our study, agomelatine significantly decreased HVA levels in the group treated with agomelatine and it was also found that psychotic-like behavior significantly decreased.…”

Section: Discussionmentioning

confidence: 99%

Agomelatine Protection in an LPS-Induced Psychosis-Relevant Behavior Model

Inanir¹,

Çöpoğlu

Kokacya

et al. 2015

Med Sci Monit

View full text Add to dashboard Cite

BackgroundThe aim of this study was to investigate the effect of agomelatine in a psychosis-relevant behavior model.Material/MethodsWe used 18 adult male Wistar rats in this study. Twelve rats given LPS for endotoxemia were randomly divided into 2 groups (n=6). Group I was treated with 1 mL/kg 0.9% NaCl i.p. and Group II was treated with 40 mg/kg agomelatine. Six normal rats served as the control group and were not given LPS for endotoxemia. Cylindrical steel cages containing vertical and horizontal metal bars with top cover were used. Rats were put in these cages for the purpose of orientation for 10 min. Apomorphine was given to rats removed from cages, and then they were immediately put back in the cages for the purpose of observing stereotyped conduct. Brain HVA levels and plasma TNF-α levels were evaluated in tissue homogenates using ELISA. The proportion of malondialdehyde (MDA) was measured in samples taken from plasma for detection of lipid peroxidation similar to thiobarbituric acid reactive substances.ResultsLPS induced-plasma TNF-α, brain TNF-α, and plasma MDA levels were significantly lower in the LPS+agomelatine group compared to the LPS+saline group (p<0.05). HVA levels and stereotype scores were significantly lower in the LPS+agomelatine group compared to the LPS+saline group (p <0.001).ConclusionsAgomelatine reduced TNF-α, HVA, MDA levels, and the stereotype score in relevant models of psychosis. Our results suggest that the anti-inflammatory effect of agomelatine involved oxidant cleansing properties and that its effects on the metabolism of dopamine can play an important role in the model of psychosis.

show abstract

“…Many research groups have reported that the blood concentrations of HVA or MHPG were decreased during the psychopathological improvement among patients under an acute state (Bowers et al, 1989; Davidson et al, 1991; Davila et al, 1988; Koreen et al, 1994; Miura et al, 2012 Nagaoka et al, 1997; Pickar et al, 1984; Yoshimura et al, 2010), but these results were not completely consistent in all studies of a similar kind (Zumárraga et al, 2011; Nikisch et al, 2010). Several PET studies demonstrated higher dopamine synthesis within presynaptic dopaminergic neurons in FEP patients and drug-free patients relative to that in a normal control group (Howes et al, 2012), which may partly explain the finding of elevated dopamine turnover at the very early phase as observed in the studies measuring the concentrations of monoamine in patients under FEP (Bowers et al, 1989; Davila et al, 1988; Nagaoka et al, 1997; Pickar et al, 1984).…”

Section: Discussionmentioning

confidence: 94%

Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis

et al. 2020

View full text Add to dashboard Cite

Background: Patients with first-episode psychosis respond well to initial antipsychotic treatment, but among patients experiencing a relapse of psychosis, the response rate falls to approximately 30%. The mechanism of this discrepancy has not been clarified, but the development of dopamine supersensitivity psychosis with the underlying up-regulation of post-synaptic dopamine D2 receptors could be involved in this lesser response. It is uncertain whether elevated dopamine synthesis and release occurs in patients with dopamine supersensitivity psychosis, in contrast to those with first-episode psychosis. Patients and methods: We examined a first-episode psychosis group ( n=6) and a chronic schizophrenia group, i.e. patients experiencing relapse ( n=23) including those who relapsed due to dopamine supersensitivity psychosis ( n=18). Following the initiation of treatment, we measured the patients’ blood concentrations of homovanillic acid and 3-methoxy-4-hydroxyphenylglycol at two weeks and four weeks after the baseline measurements. Results: The first-episode psychosis group tended to show decreased homovanillic acid, accompanied by an improvement of symptoms. The chronic schizophrenia group showed no alteration of homovanillic acid or 3-methoxy-4-hydroxyphenylglycol over the treatment period. These results were the same in the dopamine supersensitivity psychosis patients alone. Conclusions: Our findings suggest that unlike first-episode psychosis, the release of dopamine from presynaptic neurons did not increase in relapse episodes in the patients with dopamine supersensitivity psychosis. This indirectly indicates that the development of supersensitivity of post-synapse dopamine D2 receptor is involved in relapse in dopamine supersensitivity psychosis patients.

show abstract

Variability of Plasma Homovanillic Acid Over 13 Months in Patients with Schizophrenia; Relationship with the Clinical Response and the Wisconsin Card Sort Test

Cited by 5 publications

References 54 publications

Relationship between Plasma Homovanillic Acid and Outcome in Patients with Psychosis Spectrum Disorders

Relationship between Plasma Homovanillic Acid and Outcome in Patients with Psychosis Spectrum Disorders

Agomelatine Protection in an LPS-Induced Psychosis-Relevant Behavior Model

Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis

Contact Info

Product

Resources

About